This page is updated frequently with new Proteins-related patent applications.
|| List of recent Proteins-related patents
|Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing gipcr signaling in scoliotic subjects|
Methods of stratifying a subject having or at risk for developing adolescent idiopathic scoliosis (ais) into diagnostically or clinically useful subclasses are provided. The stratification is based on the subject's giα protein serine phosphorylation profile and/or the degree of imbalance in g-protein coupled receptor responses to giα and gsα protein stimulation.
|Direct, programmable detection of epigenetic dna cytosine modifications using tal effectors|
The present invention relates to methods for the differentiation of a 5-hydroxymethyl modification of a cytosine residue of interest in a nucleic acid molecule from (i) a 5-methyl modification of said cytosine residue of interest o,r (ii) said unmodified cytosine residue of interest, said methods making use of the capability of transcription-activator-like effector (tale) proteins to preferentially bind with strong affinity to nucleic acid sequences containing non-modified cytosine residues or 5-methyl modified cytosine residues, and to bind, if at all, with only strongly reduced affinity to nucleic acid sequences containing 5-hydroxymethyl modified cytosine residues. The present invention further relates to respective uses of tale proteins for the differentiation of a 5-hydroxymethyl modification of a cytosine residue of interest in a nucleic acid molecule from (i) a 5-methyl modification of said cytosine residue of interest or (ii) said unmodified cytosine residue of interest..
|Methods and systems for determining spatial patterns of biological targets in a sample|
The present disclosure provides methods and assay systems for use in spatially encoded biological assays, including assays to determine a spatial pattern of abundance, expression, and/or activity of one or more biological targets across multiple sites in a sample. In particular, the biological targets comprise proteins, and the methods and assay systems do not depend on imaging techniques for the spatial information of the targets.
Prognosys Biosciences, Inc.
|Methods and kits for labeling cellular molecules|
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided.
University Of Washington
|Method of detection of gram-negative bacteria periplasmic space and cell wall outer membrane proteins by mass spectrometry|
The invention relates to a method of detection of gram-negative bacteria periplasmic space and cell wall outer membrane proteins by mass spectrometry, wherein the periplasmic space and cell wall outer membrane proteins are extracted from the bacteria, and the proteins to be detected are stabilized by an inhibitor and/or a substrate of the given protein, the proteins are then dissolved, placed onto a maldi-tof plate, covered with matrix solution, measured by maldi-tof mass spectrometry, and the resulting spectra are compared to the reference peaks of the given protein. Preferably, the proteins are beta-lactamases and their detection can be used to quickly determine the bacterial resistance against beta-lactam antibiotics, minimizing the false-positive results..
Univerzita Karlova V Praze, Lekarska Fakulta V Plzni
|Methods for the expression of peptides and proteins|
The present invention lies in the field of molecular biology, recombinant peptide and protein expression and relates to methods comprising nucleic acid sequences comprising allocrites of t1sss or fragments thereof for the efficient production of recombinant pe ois and pr oi. The allocrites or fragments thereof improve the expression of peoi and pr oi as ib and function as ib-tags..
|Methods for controlling fucosylation levels in proteins|
The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions..
Center Of Molecular Immunology
|Methods to control protein heterogeneity|
The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the heterogeneity of proteins expressed in host cells.. .
|Yeast with increased butanol tolerance involving cell wall proteins|
Provided herein are recombinant yeast host cells and methods for their use for production of fermentation products from a pyruvate utilizing pathway. The yeast host cells provided herein comprise at least one genetic modification in a pyruvate decarboxylase gene and at least one genetic modification in an endogenous cell wall protein, which confers resistance to butanol and increased glucose utilization..
Butamax Advanced Biofuels Llc
|Improved polynucleotide sequences encoding tale repeats|
The present invention is in the field of the gene editing molecular tools. The present invention relates to rewritten nucleic acid sequences encoding repeated dna recognition motifs of tale (transcription activator-like effector) proteins.
Novel genes involved in biosynthesis
The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited
Protein production in plants
The present disclosure relates to methods and constructs for producing heterologous peptides and proteins in plants in a safe and controlled manner. One aspect of the present invention provides a method of producing heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest and a marker gene, a nucleotide sequence capable of suppressing patatin expression, along with a nucleotide sequence capable of suppressing cd4b expression, and/or a nucleotide sequence capable of overexpressing p19.
J.r. Simplot Company
The present disclosure relates to a method of preparing exonuclease resistant molecules of block-decoys, use of the molecules in methods of modulating expression of recombinant proteins, particularly in vitro, for example by down regulation or inhibition of one or more transcription factors, and novel molecules of block-decoys, especially those obtained or obtainable from the methods herein. The disclosure also relates to use of said block decoys in vitro and in therapy.
Ucb Biopharma Sprl
Method for purifying active gla-domain coagulation proteins
The invention relates to a method for purifying biologically active gla-domain coagulation proteins, comprising the following steps: a) bringing a sample that contains one or more gla-domain coagulation proteins and may contain biologically inactive molecules of gla-domain protein(s), into contact with an affinity support on which nucleic aptamers that bind specifically to at least one biologically active gla-domain coagulation protein are immobilized, in order to form complexes between (i) said nucleic aptamers and (ii) said gla-domain coagulation protein(s), b) releasing the gla-domain coagulation protein(s) from the complexes formed in step a), and c) recovering said biologically active gla-domain coagulation protein(s) in a purified form.. .
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
Transglycosylation activity of glycosynthase mutants of an endo-beta-n-acetylglucosaminidase (endo-d) from streptococcus pneumoniae
The present invention provides for recombinant endo-d and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated glcnac-protein acceptor by transglycosylation. Such recombinant endo-d and selected mutants are useful for efficient glycosylation remodeling of igg1-fc domain..
University Of Maryland, Baltimore
Method of suppressing gene transcription through histone lysine methylation
The present invention relates to methods of suppressing the transcriptional expression of one or more genes by methylating the chromatin histone proteins of the one or more genes. Specifically, a viral set domain histone lysine methyltransferase (vset or vset-like protein) methylates lysine 27 of a gene's histone protein 3 (h3-k27) thereby suppressing the transcription of the gene..
Icahn School Of Medicine At Mount Sinai
Oncostatin m receptor antigen binding proteins
The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Biogen Ma Inc.
Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human igf-1r and human erbb3. Exemplary antibodies inhibit signal transduction through either or both of igf-1r and erbb3.
Merrimack Pharmaceuticals, Inc.
Stabilized receptor polypeptides and uses thereof
The present invention provides stabilized activin iib receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins.
Fusion proteins with dual receptor agonist activities
The present disclosure relates to heterodimeric fusion proteins comprising two polypeptides, the first polypeptide comprising a first peptide (p1), a linker (l1), and a fc region (f1), the second polypeptide comprising a second peptide (p2), a linker (l2), and an fc region (f2), wherein p1 and p2 are each independently selected from glp-1, glp-1 analogues, glucagon, glucacon analogues, gip, gip analogues, oxyntomodulin, oxyntomodulin analogues, exendin and exendin analogues; wherein f is selected from an igg fc, an iga fc, an ige fc, an iggm fc, and their analogues; wherein the c-terminals of the peptides are linked, though the linker l, to the n-terminals of the fc region f. In one embodiment, the fusion proteins disclosed herein have agonist activity against at least two of the glp-1 receptor, the gip receptor, and the glucagon receptor..
Askgene Pharma, Inc.
Il-1 family variants
The present invention provides compositions and methods relating to il-1rrp2 requiring proteins.. .
Colon disease targets and uses thereof
The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (ccat) and antibodies binds to ccat.
Refolding of recombinant proteins
Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high ph buffer.. .
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
And methods of use to inhibit the interaction of menin with mll1, mll2 and mll-fusion oncoproteins.. .
Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human hox genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event.
Portage Pharmaceuticals Ltd.
Method for producing autologous proteins
A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
Pharmaceutical compositions of anisomelic acid and the use thereof
A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of anisomelic acid or salts thereof. The pharmaceutical composition may comprise anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof.
Treatment of autophagy-related disorders
The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or trim proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions..
Computer-implemented methods of determining protein viscosity
The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag
Protein and antibody profiling using small molecule microarrays
Aspects of the present invention describe methodology by which arrays of synthetic molecules can be created and employed for various types of proteomics profiling experiments. The most important of these from a clinical standpoint are the visualization of antibody and t cell binding patterns, which could be employed as a tool for monitoring the state of the immune system of a patient.
The Board Of Regents Of The University Of Texas System
Tumor marker, monoclonal antibodies and methods of use thereof
Newly identified proteins as markers for the detection of colon, ovary, kidney, esophagus and prostate tumors, or as therapeutic targets for their treatment; affinity ligands and particularly antibodies capable of selectively interacting with the tumor markers and methods for tumor diagnosis and thereapy using such antibodies.. .
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
The invention described herein relates to novel genes and their encoded proteins, termed mutants associated with resistance to sti-571 (e.g., t315i bu-abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express mars. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of mars..
The Regents Of The University Of California
Mass spectrometric diagnosis of septicemia
The invention mainly relates to the mass spectrometric identification of pathogens in blood cultures from bloodstream infections (septicemia). The invention provides a method with which microbial pathogens can be separated in purified form from blood after a relatively brief cultivation in a blood culture flask, without any interfering human proteins or any residual fractions of blood particles such as erythrocytes and leukocytes, and can be directly identified by mass spectrometric measurement of their protein profiles.
Bruker Daltonik Gmbh
Harvest operations for recombinant proteins
The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where do2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable dhna-recombinant protein adduct, as measured by an iec assay at 310 nm. The present invention also contemplates a method of producing a recombinant protein comprising (a) fermenting a mene gene-deleted prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, (b) harvesting said recombinant protein; and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable dhna-recombinant protein adduct, as measured by an iec assay at 310 nm, and wherein the recombinant protein yield is increased by about 20% or greater..
Artificial dna sequence with optimized leader function in 5'(5'-utr) for the over-expression of recombinant proteins in plants and the production of recombinant proteins in plants
Artificial dna of a 5′-utr leader region, which artificial dna is effective in increasing the expression of recombinant proteins in plants, and comprises, along the 5′→3′ direction, an inr initiator site and a kozak or kozak-like consensus sequence, and also comprises, between the inr initiator site and the kozak or kozak-like consensus sequence, a plurality of poly(caa) and a plurality of poly(ct) regions, in the same number as the poly(caa) regions wherein at least one, optionally each one, poly(caa) region, in the 5′→3′ direction, is upstream of a poly(ct) region and at least one poly(caa) region, in the 5′→3′ direction, is contiguous with a poly(ct) region, wherein the artificial dna provides the absence of a/t-rich motifs, the absence of trinucleotide elements att, the absence of trinucleotide elements ctg and the absence of homopolymeric tracts, that is, sequences consisting of more than 3, optionally more than 4, identical nucleotides.. .
Roding Holding S.a.
Nucleotide sequence motifs directing nucleic acid location to extracellular vesicles
The present invention discloses the use of isolated short sequence motifs capable of directing or packaging regulatory nucleic acids, preferably rnas, into extracellular vesicles, preferably exosomes. This mechanism is enhanced by the binding of hnrnp family proteins, which are sumoylated, to such nucleic acid.
Universidad Autonoma De Madrid (uam)
Thermophilic and thermoacidophilic glycosylation genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods
Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for glycosylating and/or post-translationally modifying proteins using isolated and/or purified polypeptides and nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc.
Antibodies to human signal peptide-containing proteins
The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Cmv neutralizing antigen binding proteins
The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (cmv). Also encompassed by the invention are antigen binding proteins that have been humanized.
Board Of Regents Of The University Of Texas System
Method for producing hypo-metallated redox-active metallothionein protein and pharmaceutical composition containing the same
The present invention relates to method for producing hypo-metallated redox-active metallothionein (mt) proteins, pharmaceutical compositions containing the proteins, and uses the pharmaceutical compositions for treatment of conditions originating from elevated intracellular oxidative stress and/or dis-balanced intracellular redox-potential and/or redox-potential-dependent imbalance of metal ions.. .
C1 inhibitor fusion proteins and uses thereof
The present invention provides, among other things, methods and compositions for treating complement mediated disease, in particular, chronic diseases requiring prophylactic and/or maintenance treatment. In one aspect, c1-inh fusion proteins having longer half-life than native plasma-derived c1-inh are provided.
Shire Human Genetic Therapies, Inc.
Optimized non-canonical zinc finger proteins
Disclosed herein are zinc fingers comprising cchc zinc coordinating residues. Also described are zinc finger proteins and fusion proteins comprising these cchc zinc fingers as well as polynucleotides encoding these proteins.
Sangamo Biosciences, Inc.
Compounds and methods for trans-membrane delivery of molecules
A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of sirna the delivery system comprises conjugation of the macromolecule drug to a moiety that enables effective passage through the membranes. Respectively, novel compounds and pharmaceutical compositions are provided, utilizing said delivery system.
Nanocomplexes of modified peptides or proteins
A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a ph responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof..
Mutated non-primate lentiviral env proteins and their use as drugs
A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.. .
Centre National De La Recherche Scientifique
Immungenic tp0751 fragments
The present application provides methods of stimulating an immune response, such as a protective immune response against treponema pallidum infection. Such methods utilize fragments of the tp0751 protein (such as any of seq id nos: 3-10, those n-terminally truncated from amino acids 1 through 77, 1 through 114, or anywhere in between, e.g., those that start at any amino acid from 78 to 115).
Uvic Industry Partnerships Inc.
Interferon lambda-antibody complexes
The present invention concerns methods and compositions for forming complexes of interferon-λ with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-λ and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (ddd) moiety from human protein kinase a or an anchor domain (ad) moiety from an a-kinase anchoring protein (akap).
Ibc Pharmaceuticals, Inc.
Mic-1 fusion proteins and uses thereof
The invention relates to mic-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a mic-1 protein or an analogue thereof at the c-terminus of the fusion protein and a functional variant of human serum albumin at the n-terminus of the fusion protein connected via a peptide linker.
Novo Nordisk A/s
Rhomboid proteins and uses thereof
Compositions and methods for managing the growth, life cycle, functionality, or biological progression of cells, tissues, and organisms by introducing rhomboid proteins or peptides into the internal and external environment of the cells, tissues, and organisms. In particular, embodiments comprise compositions and methods for overcoming drug resistance in disease, and for sensitizing cells, tissues, and organisms to agents to treat disease, and methods for producing such compositions.
Queen's University At Kingston
Method for inhibiting hiv replication in mammal and human cells
The present invention describes a method to inhibit replication of the human immunodeficiency virus (hiv) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la the replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering rna and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the hiv infection.
Centro De Ingeniería Genetica Y Biotecnología
Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.. .
The present invention relates to compositions and methods of formulating nanoparticle drugs for cancer treatment in particular for intravenous administration in particular nanoparticle formulations containing cytotoxic drugs for the treatment of cancer. The compositions may have properties which facilitate the release of drugs into the patient including being unstable in plasma/blood, having low auc, low cmax, high vd, cmc above theoretical cmax of the drug, high tumor/plasma auc.
Surgical instruments for tensioning tissue
A surgical instrument can comprise an end effector including a plurality of jaws which can be configured to compress tissue therebetween. The end effector can further comprise one or more electrodes which can be configured to direct a flow of electrical current through the tissue in order to heat the tissue and denature collagen and/or other proteins within the tissue.
Ethicon Endo-surgery, Llc
Double-stranded ribonucleic acid as control against insects
A composition for use in formulations for controlling insect populations, including populations of mosquito and flies. The composition comprises one or more double-stranded constructs inhibitory to rna transcription of ribosomal proteins.
United States Of America As Represented By The Secretary Of Agriculture
Identification of minimal combinations of oncoproteins in notch pathway to suppress human glioblastoma
The invention is directed to in-silico method to identify combinatorial oncoprotiens as potential drug targets or combinatorial oncoprotien biomarkers in notch pathway to suppress the human glioblastoma proliferation.. .
Council Of Scientific & Industrial Research
Detection of protein to protein interactions
The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments.
The Governing Council Of The University Of Toronto
Method of traceless labeling glycoproteins on surface and application thereof
The present invention relates to a method of traceless labeling glycoproteins on a surface and an application thereof. A test glycoprotein can be immobilized on a surface using a ba-tosyl probe and the ba-tosyl probe is then released using a releasing agent, so as to expose a glycan residue of the test glycoprotein.
National Sun Yat-sen University
Method for measuring cell-to-cell transmission of alpha-synuclein aggregates using bimolecular fluorescence complementation screening a substance for preventing or treating neurodegenerative disease using the same
The present disclosure relates to dual-cell model and caenorhabditis elegans model systems for measuring neuron-to-neuron transmission of protein aggregates, and more particularly to transgenic cell and animal model systems expressing fusion proteins of n-terminus or c-terminus of fluorescent proteins with α-synuclein proteins, methods for measuring continuous cell-to-cell transmission of α-synuclein aggregates using the same, and methods for screening substances for preventing or treating neurodegenerative diseases.. .
Konkuk University Industrial Cooperation Corp
Modified membrane spanning proteins and methods for the preparation and use thereof
In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like.
Abilita Bio, Inc.
Rna/prtein/dna preferential fluid sample collection system and methods
Apparatus and methods are provided to obtain rna-enhanced and protein-enhanced fluid samples which are stable at ambient temperatures. An apparatus includes a filter element made from a fibrous hydrophilic material which preferentially binds and filters cells, dna-containing macrostructures, mucins and particulates, but does not preferentially bind rna, rna-containing macrostructures or proteins.
Oasis Diagnostics Corporation
Microalgae of the genus euglena, producing polysaccharides, and producing organic compound
Provided are microalgae of the genus euglena that fall under euglena gracilis strain eod-1 (accession no. Ferm bp-11530) or its mutant strain and that are capable of producing at least polysaccharides.
Kobelco Eco-solutions Co., Ltd.
Plants having increased resistance to pathogens and producing said plants
The invention relates to a plant having increased resistance to pathogens, wherein the protein sobir1 from arabidopsis thaliana or a homologous protein, which is capable of interacting with at least one of the prr receptor proteins rlp30 or rlp1, and at least one of the prr receptor proteins rlp30 or rlp1 are overexpressed in comparison with the wild-type plant or are newly synthesized. The pathogens are preferably fungi, in particular from the genus sclerotinia, and bacteria, in particular from the genus xanthomonas.
Eberhard Karls UniversitÄt TÜbingen
Novel molecules of the card-related protein family and uses thereof
Novel card-9, card-10, or card-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated card-9, card-10, or card-11 proteins, the invention further provides card-9, card-10, or card-11, fusion proteins, antigenic peptides and anti-card-9, card-10, or card-11 antibodies.
Millennium Pharmaceuticals, Inc.
Surface modification method and surface modification body
Provided are methods for surface-modifying a rubber vulcanizate or a thermoplastic resin, which can provide chemically fixed surfaces showing low adsorption properties or selective adsorption properties with respect to proteins and cells, as well as excellent durability, instead of coatings which have drawbacks, such as that the performance is reduced due to separation or peeling of the coating. The present invention relates to a method for surface-modifying an object made of a rubber vulcanizate or a thermoplastic resin, the method including: a step 1 of forming polymerization initiation points on the surface of the object; and a step 2 of radically polymerizing a hydrophilic monomer starting from the polymerization initiation points by irradiation with uv light having a wavelength of 300 to 400 nm to grow polymer chains on the surface of the object..
Sumitomo Rubber Industries, Ltd.
Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant dll4 and/or vegf expression or activity.. .
Antibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.
Engineered intein for improved production of protein-intein fusions
The invention discloses engineered non-self-cleaving inteins derived from mxe gyra inteins and methods of using such inteins to chemically modify proteins.. .
Wisconsin Alumni Research Foundation
Composition comprised of antigen linked to a tnf superfamily ligand
The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of tnf superfamily (tnfsf) ligands. The tnfsfs serve as vaccine adjuvants for increasing the immune response to the antigens.
Cartilage-binding fusion proteins
Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided..
Merrimack Pharmaceuticals, Inc.
Homeodomain fusion proteins and uses thereof
Provided herein are fusion proteins comprising a homeodomain fusion protein domain and a transcription modulator domain for treatment of various diseases or disorders such as cancer. The homeodomain fusion protein domain binds to a target gene and the transcription modulator domain either activates or represses gene transcription.
The General Hospital Corporation D/b/a Massachusetts General Hospital
Polypeptides having nucleic acid binding activity
Polynucleotides having nucleic acid binding activity are provided. Methods of stabilizing a nucleic acid duplex are provided.
Applied Biosystems, Llc